Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

ladyPI

Renmanco

To: drtom1234 who wrote (45940)	4/28/2018 11:54:17 PM
From: idahoranch1	2 Recommendations Read Replies (1) of 63276

Whatever the plans, I’m sure it’s because of communication with FDA and how they prefer the company to proceed given the multiple indications 132 targets. The company had to be requesting the best greased skids to get as many indications approved in the best timeframe they could. Hopefully it’s the best options for us for the best pathways. It would be great to get a pleasant surprise, but I’m going to try to avoid raising my expectations on that to avoid disappointment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next